Literature DB >> 25732448

Ethics and policy issues for stem cell research and pulmonary medicine.

Justin Lowenthal1, Jeremy Sugarman2.   

Abstract

Stem cell research and related initiatives in regenerative medicine, cell-based therapy, and tissue engineering have generated considerable scientific and public interest. Researchers are applying stem cell technologies to chest medicine in a variety of ways: using stem cells as models for drug discovery, testing stem cell-based therapies for conditions as diverse as COPD and cystic fibrosis, and producing functional lung and tracheal tissue for physiologic modeling and potential transplantation. Although significant scientific obstacles remain, it is likely that stem cell-based regenerative medicine will have a significant clinical impact in chest medicine. However, stem cell research has also generated substantial controversy, posing a variety of ethical and regulatory challenges for research and clinical practice. Some of the most prominent ethical questions related to the use of stem cell technologies in chest medicine include (1) implications for donors, (2) scientific prerequisites for clinical testing and use, (3) stem cell tourism, (4) innovation and clinical use of emerging stem cell-based interventions, (5) responsible translation of stem cell-based therapies to clinical use, and (6) appropriate and equitable access to emerging therapies. Having a sense of these issues should help to put emerging scientific advances into appropriate context and to ensure the responsible clinical translation of promising therapeutics.

Entities:  

Mesh:

Year:  2015        PMID: 25732448      PMCID: PMC4364318          DOI: 10.1378/chest.14-1696

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  79 in total

1.  Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.

Authors:  Ronald K F Fung; Ian H Kerridge
Journal:  Bioethics       Date:  2011-07-04       Impact factor: 1.898

Review 2.  Regenerative medicine and stem cells: prometheus revisited.

Authors:  Demosthenes Bouros; Geoff Laurent
Journal:  Respiration       Date:  2012-11-27       Impact factor: 3.580

3.  Lung disorders: a new model and modulator of pulmonary oedema.

Authors:  Charlotte Harrison
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 4.  Introduction to stem cells and regenerative medicine.

Authors:  George Kolios; Yuben Moodley
Journal:  Respiration       Date:  2012-12-13       Impact factor: 3.580

5.  Questions concerning the clinical translation of cell-based interventions under an innovation pathway.

Authors:  Jeremy Sugarman
Journal:  J Law Med Ethics       Date:  2012       Impact factor: 1.718

6.  Experimental treatments: Regulating stem-cell therapies worldwide.

Authors:  Margaret Sleeboom-Faulkner
Journal:  Nature       Date:  2013-03-07       Impact factor: 49.962

7.  Which patient groups should be asked to participate in first-in-human trials of stem-cell-based therapies?

Authors:  Kristina Hug; Göran Hermerén
Journal:  J Clin Ethics       Date:  2012

8.  Evaluating the first-in-human clinical trial of a human embryonic stem cell-based therapy.

Authors:  Audrey R Chapman; Courtney C Scala
Journal:  Kennedy Inst Ethics J       Date:  2012-09

Review 9.  Concise review: clinical prospects for treating chronic obstructive pulmonary disease with regenerative approaches.

Authors:  Hiroshi Kubo
Journal:  Stem Cells Transl Med       Date:  2012-07-24       Impact factor: 6.940

10.  Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent.

Authors:  Justin Lowenthal; Scott Lipnick; Mahendra Rao; Sara Chandros Hull
Journal:  Stem Cells Transl Med       Date:  2012-05-08       Impact factor: 6.940

View more
  5 in total

1.  Hope vs. caution: ethical and regulatory considerations for neonatal stem cell therapies.

Authors:  Naomi T Laventhal; Scott A Rivkees; Valerie P Opipari
Journal:  Pediatr Res       Date:  2018-01-10       Impact factor: 3.756

2.  rhBMP2 alone does not induce macrophage polarization towards an increased inflammatory response.

Authors:  Emily L Durham; Rajiv Kishinchand; Zachary J Grey; James J Cray
Journal:  Mol Immunol       Date:  2019-11-20       Impact factor: 4.407

3.  Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways.

Authors:  Armel Herve Nwabo Kamdje; Paul Takam Kamga; Richard Tagne Simo; Lorella Vecchio; Paul Faustin Seke Etet; Jean Marc Muller; Giulio Bassi; Erique Lukong; Raghuveera Kumar Goel; Jeremie Mbo Amvene; Mauro Krampera
Journal:  Cancer Biol Med       Date:  2017-05       Impact factor: 4.248

4.  Efficient Differentiation of Mouse Induced Pluripotent Stem Cells into Alveolar Epithelium Type II with a BRD4 Inhibitor.

Authors:  Toru Momozane; Eriko Fukui; Soichiro Funaki; Makoto Fujii; Yuhei Kinehara; Emiko Ito; Shigeru Miyagawa; Yuko Ohno; Yoshiki Sawa; Meinoshin Okumura; Yasushi Shintani
Journal:  Stem Cells Int       Date:  2019-12-27       Impact factor: 5.443

5.  Autologous transplantation of adipose-derived stromal cells combined with sevoflurane ameliorates acute lung injury induced by cecal ligation and puncture in rats.

Authors:  Zuodi Liang; Heng Zhou; Rurong Tang; Shuo Zhang; Xiaohuan Chen; Ling Pei
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.